Last reviewed · How we verify
dinoprostone vaginal delivery system
Dinoprostone vaginal delivery system, marketed by University Medical Centre Ljubljana, is a prostaglandin E2 formulation used for cervical ripening and induction of labor. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | dinoprostone vaginal delivery system |
|---|---|
| Sponsor | University Medical Centre Ljubljana |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction (PHASE3)
- Comparison of the Effectiveness, Safety, and Satisfaction of Different Methods for Labor Induction (PHASE4)
- DOuble-BAlloon Versus PROstaglandin E2 for Cervical Ripening in Low Risk Pregnancies (NA)
- Dinoprostone Induction vs. Expectant Management After PROM at Term (PHASE4)
- An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt (PHASE3)
- Modality of Induction of Labor in Obese Women at Term (MODOBAT)
- Propess Versus Prostin for Induction of Labour in Women With Term PROM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: